US CDC Recommends Expanding Pneumococcal Vaccines to Adults Aged 50-64
The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The agency's earlier recommendation for vaccination was for adults 65 years or older and children younger than 5,
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
GlobalData on MSN1d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adultsAbrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Watch Toronto's #1 morning show for the latest news, weather and traffic from across the GTA.
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its ...
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...
Experiments with mice that received repeated mRNA vaccination showed evidence of neutralizing antibody–producing cells in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback